Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Sarah A Holstein, J. Christine Ye, Alan Howard, Manisha Bhutani, Nicole Gormley, Theresa Hahn, Jens Hillengass, Amrita Krishnan, C. Ola Landgren, Nikhil C. Munshi, Stefania Oliva, Roger G. Owen, Marcelo C. Pasquini, Noemi Puig, Niels Weinhold, Katja Weisel, Philip L. McCarthy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

Original languageEnglish (US)
Pages (from-to)e89-e97
JournalBiology of Blood and Marrow Transplantation
Volume25
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Residual Neoplasm
Bone Marrow
Clinical Trials
Transplants
Education
Hematology
Research Personnel
Research

Keywords

  • Autologous stem cell transplantation
  • Endpoint
  • Immune profiling
  • Minimal residual disease
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. / Holstein, Sarah A; Ye, J. Christine; Howard, Alan; Bhutani, Manisha; Gormley, Nicole; Hahn, Theresa; Hillengass, Jens; Krishnan, Amrita; Landgren, C. Ola; Munshi, Nikhil C.; Oliva, Stefania; Owen, Roger G.; Pasquini, Marcelo C.; Puig, Noemi; Weinhold, Niels; Weisel, Katja; McCarthy, Philip L.

In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 3, 01.03.2019, p. e89-e97.

Research output: Contribution to journalArticle

Holstein, SA, Ye, JC, Howard, A, Bhutani, M, Gormley, N, Hahn, T, Hillengass, J, Krishnan, A, Landgren, CO, Munshi, NC, Oliva, S, Owen, RG, Pasquini, MC, Puig, N, Weinhold, N, Weisel, K & McCarthy, PL 2019, 'Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling', Biology of Blood and Marrow Transplantation, vol. 25, no. 3, pp. e89-e97. https://doi.org/10.1016/j.bbmt.2018.11.001
Holstein, Sarah A ; Ye, J. Christine ; Howard, Alan ; Bhutani, Manisha ; Gormley, Nicole ; Hahn, Theresa ; Hillengass, Jens ; Krishnan, Amrita ; Landgren, C. Ola ; Munshi, Nikhil C. ; Oliva, Stefania ; Owen, Roger G. ; Pasquini, Marcelo C. ; Puig, Noemi ; Weinhold, Niels ; Weisel, Katja ; McCarthy, Philip L. / Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. In: Biology of Blood and Marrow Transplantation. 2019 ; Vol. 25, No. 3. pp. e89-e97.
@article{a04ff8be21cf4234bb04be2d0269803b,
title = "Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling",
abstract = "The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.",
keywords = "Autologous stem cell transplantation, Endpoint, Immune profiling, Minimal residual disease, Multiple myeloma",
author = "Holstein, {Sarah A} and Ye, {J. Christine} and Alan Howard and Manisha Bhutani and Nicole Gormley and Theresa Hahn and Jens Hillengass and Amrita Krishnan and Landgren, {C. Ola} and Munshi, {Nikhil C.} and Stefania Oliva and Owen, {Roger G.} and Pasquini, {Marcelo C.} and Noemi Puig and Niels Weinhold and Katja Weisel and McCarthy, {Philip L.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.bbmt.2018.11.001",
language = "English (US)",
volume = "25",
pages = "e89--e97",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

AU - Holstein, Sarah A

AU - Ye, J. Christine

AU - Howard, Alan

AU - Bhutani, Manisha

AU - Gormley, Nicole

AU - Hahn, Theresa

AU - Hillengass, Jens

AU - Krishnan, Amrita

AU - Landgren, C. Ola

AU - Munshi, Nikhil C.

AU - Oliva, Stefania

AU - Owen, Roger G.

AU - Pasquini, Marcelo C.

AU - Puig, Noemi

AU - Weinhold, Niels

AU - Weisel, Katja

AU - McCarthy, Philip L.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

AB - The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

KW - Autologous stem cell transplantation

KW - Endpoint

KW - Immune profiling

KW - Minimal residual disease

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85057956613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057956613&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.11.001

DO - 10.1016/j.bbmt.2018.11.001

M3 - Article

VL - 25

SP - e89-e97

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -